Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk Heras et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+AZ beneficial for COVID-19? Retrospective 100 patients in Andorra Lower mortality with HCQ+AZ (p=0.004) Heras et al., European Geriatric Medicine, doi:10.1007/s41999-020-00432-w Favors HCQ Favors control
COVID-19 mortality risk factors in older people in a long-term care center
Heras et al., European Geriatric Medicine, doi:10.1007/s41999-020-00432-w (date from earlier preprint)
Heras et al., COVID-19 mortality risk factors in older people in a long-term care center, European Geriatric Medicine, doi:10.1007/s41999-020-00432-w (date from earlier preprint)
Sep 2020   Source   PDF  
  All Studies   Meta
Retrospective 100 COVID+ elderly nursing home patients, HCQ+AZ mortality 11.4% vs. control 61.9%, RR 0.18, p<0.001. Median age 85.
risk of death, 95.6% lower, RR 0.04, p = 0.004, treatment 8 of 70 (11.4%), control 16 of 30 (53.3%), NNT 2.4, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Heras et al., 2 Sep 2020, retrospective, Andorra, peer-reviewed, median age 85.0, 13 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: European Geriatric Medicine (2021) 12:601–607 RESEARCH PAPER COVID‑19 mortality risk factors in older people in a long‑term care center Eva Heras1 · Pablo Garibaldi1 · Maite Boix1 · Oliver Valero2 · Jorge Castillo1 · Yurisan Curbelo1 · Elso Gonzalez1 · Obilagilio Mendoza1 · Maria Anglada1 · Joan Carles Miralles1 · Petra Llull1 · Ricard Llovera1 · Josep M. Piqué1 Received: 18 August 2020 / Accepted: 11 November 2020 / Published online: 27 November 2020 © European Geriatric Medicine Society 2020 Key summary points Aim COVID-19 mortality risk factors in older people from a long term care center. Findings Male gender, low Barthel index, no pharmacological treatment and lymphocytopenia are independent mortality risk factors. Message The independent prognostic factors identified in the present study can help to adjust the healthcare resources in this population in case of new outbreaks of the COVID-19 pandemic. Abstract Purpose Despite high rates of COVID-19 infection and increased related mortality have been reported among older adults admitted in long-term care facilities, a limited amount of information is available about the natural course of this pandemic and prognostic factors in such population. In the current study, we aimed to investigate the epidemiologic, demographics, clinical, or therapeutic factors that may predict the prognosis in a cohort of COVID-19 infected institutionalized older in a nursing home. Methods We conducted a retrospective analysis of all COVID-19 confirmed institutionalized older in a nursing home from March 15 to June 5, 2020. Epidemiological, demographic, and frailty status before infection, and clinical, laboratory, treatment, and outcome data during infection were collected. We used bivariate analysis and multivariate logistic regression to identify risk factors for mortality. Results The analysis comprised all 100 COVID-19 confirmed cases during the study period. The median age was 85 years; 62% were female. The case fatality rate was 20%. In the bivariate analysis, male gender, fever, respiratory symptoms, severe cognitive decline, a low Barthel index, and lymphocytopenia were significantly associated with mortality. Patients treated with hydroxychloroquine plus azithromycin were related to a higher chance of survival than those without pharmacological treatment. Multivariate logistic regression analysis identified male gender, low Barthel index, no pharmacological treatment, and lymphocytopenia as independent risk factors associated with mortality. Conclusions Male gender, low Barthel index, and lymphocytopenia are independent risk factors for COVID-19 mortality in institutionalized older patients in long-term care nursing homes. Treatment with hydroxychloroquine and azithromycin was associated with lower mortality in these patients.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop